pathway is probably the most explored next-generation target for breast cancer therapy, and several downstream signal transducers, such as RAS, AKT or CDKs, are also currently considered as cancer targets (Weickhardt et al, 2010; Wheeler et al, 2010) . The EGFR pathway controls the expression of several miRNAs (Avraham et al, 2010; Garofalo et al, 2011) , and some transcription factors and cell cycle regulators downstream of EGFR are known to be regulated by miRNAs at different levels (Avraham et al, 2010; . However, current information is scarce and typically describes single interactions between a miRNA and a relevant target transcript. Uhlmann et al (2012) used a genome-wide library of miRNA mimics to test their effect on the expression of 26 proteins in the EGFR-driven cell cycle pathway using reverse-phase protein arrays. Their findings validated some of the miRNA-protein interactions already known, such as the control of KRAS by miR-143 or the regulation of EGFR by miR-7 (Chen et al, 2009; Webster et al, 2009 ). In addition, other phenotypic interactions were found between 241 miRNAs and 25 EGFR network transcripts, revealing a total of 355 edges connecting them (Uhlmann et al, 2012) .
The high density of connections led the authors to investigate possible associations among the identified inter-
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Cell membrane Similarly, miRNAs simultaneously modulate several of these downstream pathways to effect cell cycle progression. For instance, miR-124 co-downregulates AKT2, p38MAPK and STAT3 to inhibit the EGFR pathway leading to CDK downregulation, p27 Kip1 upregulation and cell cycle inhibition. miR-147 also participates in AKT2 downregulation and simultaneously represses Cyclins (Cyc). These two examples show how a single miRNA can target several components of a signaling pathway and how two miRNAs can co-regulate the same target. These data also suggest the therapeutic value of miR-124 and miR-147 in treating EGFR-dependent tumors. Only a few representative molecules are shown for clarity.
actions. Using a novel framework for complex network analysis, they found that proteins controlling the EGFR-driven G1/S transition are frequently co-regulated by several miRNAs (Figure 1 ). For instance, independent expression of 19 miRNAs led to the concomitant downregulation of the cyclin-dependent kinase (CDK) 4 and upregulation of p27 Kip1 , a known CDK inhibitor, and both events likely contributed to cell cycle inhibition by these miRNAs (Uhlmann et al, 2012) . The fact that the retinoblastoma protein was also concomitantly downregulated may seem surprising given the antiproliferative function of this molecule. The use of reporter assays on specific 3 0 -UTRs indicated that these changes were indirect and associated with direct co-repression of several EGFR core proteins. Thus, miR-124 was able to directly downregulate AKT2, p38MAPK and STAT3, probably resulting in the observed changes in cell cycle regulators (Figure 1) . miR-124, miR-147 and miR-193a-3p showed the highest score in the network analysis, and their expression has a significant effect in the EGFR pathway by simultaneously targeting several of its components in several different cell lines (Uhlmann et al, 2012) . As the expression of these miRNAs ultimately results in cell cycle inhibition, these three miRNAs may be relevant tumor suppressors by co-targeting several EGFR network proteins.
The fact that individual miRNAs may target several components of a single signaling pathway seems reasonably obvious. However, clear examples of this type of multi-level regulation are rare in the literature, probably due to current technical challenges, including difficulties in detecting miR-NA-protein interactions with moderate effects. The study by Uhlmann et al (2012) now provides an experimental framework to detect multiple interactions in a single pathway that may be extended to a higher number of proteins or to other pathways. The analysis of endogenous miRNAs, rather than overexpressing exogenous sequences, and the separation of direct from indirect interactions remain as major challenges in these massive studies.
A further level of complexity that needs to be clarified is how the combinational effect of several miRNAs can regulate the levels of a single protein. Although both miR-124 and miR-147 target AKT2 (Uhlmann et al, 2012;  Figure 1 ), the relevance of this co-regulation deserves further analysis. Is it additive or simply redundant? Furthermore, the p27
Kip1 family member p21 Cip1 may be regulated by 28 miRNAs (Wu et al, 2010) , and MYC, a major oncogene in several pathologies, can be targeted by nearly a dozen miRNAs with additive effects . The fact that miRNA-target sites in many proteins are not evolutionarily conserved Uhlmann et al, 2012) suggests that the combinatorial effect of several miRNAs, rather than a single miRNA, may be the critical factor for modulating the levels of specific oncogenes.
In general, it seems that individual miRNAs affect the expression of many proteins, even in the same pathway (Uhlmann et al, 2012) , but in a rather mild manner. In addition, one gene can be regulated by several miRNAs (Wu et al, 2010; . Researchers need to use new technical approaches, such as the one reported by Uhlmann et al (2012) , to characterize multiplicity, redundancy and the additive effect of miRNAs in these complex networks. These studies could identify miRNAs that may be efficient in the inhibition of a key pathway or even in the simultaneous inhibition of several pathways regulating cell survival and proliferation. The fact that AKT1 and ERK2, two major kinases in the PI3K and RAS oncogenic pathways, may be co-downregulated by 30 miRNAs (Uhlmann et al, 2012) is certainly a promising starting point that highlights the therapeutic potential of this approach. miRNAs seem to function like short, additive or redundant tweets with multiple targets, and it is now obvious that 'social' networking is essential for the effect of these sequences in cell signaling. We now need to identify the relevant networks and validate their social utility.
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